Marapharm Ventures Inc. announces final approval from the State of Nevada for first facility

 

KELOWNA, BC,  /PRNewswire/ - Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") is very pleased to announce to its shareholders, that further to its news release of October 17, 2018, its first facility has been granted the final approval to commence operations, from the State of Nevada.

Rendering - Marapharm North Las Vegas (CNW Group/Marapharm Ventures Inc.)

On Friday October 19th, the State of Nevada completed their final inspection of the first 5,000 sq. ft facility which is designated to the Company's Phenofarm Cultivation Licence. All permitting is complete for this licence and the final approval now allows for the immediate transition of plants to the new facility to complete their cycle and provide first harvest.

The Company's second 5,000 sq. ft facility, designated to the Econevada Cultivation and Processing Licences is pending final kitchen and equipment inspection.

"We are thrilled to announce the completion of the first building of our flagship cannabis facilities in North Las Vegas, which has a potential build-out to 300,000 sq. ft.  Marapharm is open for business! We are positioned to be a long-term winner in this Las Vegas market."  Linda Sampson, President and CEO

ABOUT MARAPHARM VENTURES INC.

www.marapharm.com

Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide. 

SOCIAL MEDIA:

facebook.com, twitter.com

STOCK EXCHANGES:

Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.

Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.

MARIJUANA INDUSTRY INVOLVEMENT:

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.

Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.

FORWARD - LOOKING STATEMENTS:

Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/marapharm-ventures-inc-announces-final-approval-from-the-state-of-nevada-for-first-facility-300735270.html

SOURCE Marapharm Ventures Inc.

 
 
Company Codes: OTC-QX:MRPHF, CNSX:MDM
 

Back to news